Endothelial function and atherosclerosis

Coronary Artery Disease

Volumn 10, Issue 4, 1999, Pages 241-256

  Biegelsen, Elizabeth S ^a   Loscalzo, Joseph ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Endothelium derived relaxing factor; Nitric oxide; Oxidative stress

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA CAROTENE; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE; MEVINOLIN; PROBUCOL; TETRAHYDROBIOPTERIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL FUNCTION; ENDOTHELIUM CELL; ESTROGEN THERAPY; GROWTH INHIBITION; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

EID: 0032773364     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199906000-00006     Document Type: Review

References (223)

1. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376. A seminal animal study that demonstrated that exposure of isolated rabbit aorta to acetylcholine caused vasodilatation if the endothelium was intact, but vasoconstriction if the endothelium was removed. This landmark study established the field of EDRF/NO.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84:9265-9269.
3. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-associated forms. Science 1992; 258:1898-1902.
4. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
5. Marletta MA, Yoon PS, Ihengar R, Leaf CK, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1988; 27:8706-8711.
6. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Ann Rev Pharmacol Toxicol 1985; 25:171-191.
7. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983; 53:557-573.
8. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250:H1145-H1149.
9. Cooke JP, Rossitch E Jr, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release endogenous nitrovasodilator. J Clin Invest 1991; 88:1663-1671.
10. 2 formation. N Engl J Med 1988; 319:689-698. The authors review the functions of prostacyclin in circulatory homeostasis.
11. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 1988; 95:1165-1174.
12. Pearson JD, Gordon JL. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 1979; 281:384-386.
13. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Seminars Hematol 1994; 31:261-269.
14. Miller VM, Vanhouette PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol 1985; 248:H432-H437.
15. Yanagisawa M, Kurihara H, Klimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415. In this article, the isolation of endothelin-1, a 21-amino-acid peptide, is described, and it is shown to be a potent vasoconstrictor.
16. Levin ER. Endothelins. N Engl J Med 1995; 333:356-363.
17. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, et al. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990; 66:1088-1094.
18. Dzau VJ. Vascular wall renin angiotensin pathway in control of the circulation. Am J Med 1984; 77:31-36. This review describes the features of the vascular wall renin-angiotensin system and its role in cardiovascular homeostasis. The author postulates that abnormalities in the control of this system may result in local vasospasm or systemic hypertension.
19. Kifor I, Dzau VJ. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res 1987; 60:422-428.
20. Johnson AR, Erdos EG. Metabolism of vasoactive peptides by human endothelial cells in culture. Angiotensin I converting enzyme (kininase III) and angiotensinase. J Clin Invest 1977; 59:684-695.
21. Williams GH, Hollenberg NK. Accentuated vascular and endocrine response to SQ20,881 in hypertension. N Engl J Med 1977; 287:194-201.
22. Ayuma H, Ishikawa M, Sakiyaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 80:411-415.
23. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-1058. The adhesion of human platelets to monolayers of bovine endothelial cells in culture was studied to determine the role of endothelium-derived nitric oxide in the regulation of adhesion of platelets. The results show that release of nitric oxide contributes to the nonadhesive properties of vascular endothelium.
24. 2 as inhibitors of aggregation of platelets were examined.
25. Best LC, Martin TJ, Russell RG, Preston FE. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 1997; 267:850-852.
26. MacDonald PS, Read MA, Dusting GJ. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb Res 1988; 49:181-187.
27. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90:7240-7244.
28. Shepro D, Dunham B. Endothelial cell metabolism of biogenic amines. Annu Rev Physiol 1986; 48:335-345.
29. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is ED39. J Clin Invest 1997; 99:1351-1360.
30. Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986;261:7505-7517.
31. Marcum JA, McKenney, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341-350. The authors demonstrate that contact of the hemostatic components with the endothelium enhances the rate of formation of thrombin-antithrombin complex: Heparin-like molecules present on the vascular endothelium are responsible for the antithrombin-accelerating activity.
32. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257:859-864.
33. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257:7944-7947.
34. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1982; 78:2249-2252.
35. Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59:1067-1072.
36. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68:1221-1228.
37. van Hinsbergh VWM, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65:444-451.
38. Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256:11128-11131.
39. Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986; 67:1168-1171.
40. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71:1906-1909.
41. Meyer D, Baumgartner HR. Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 1983; 54:1-9.
42. Turitto VT, Weiss HJ, Baumgartner HR. Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. J Clin Invest 1984; 74:1730-1741.
43. Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977; 74:3903-3907.
44. Hoylaerts M, Dingeman CR, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: the role of fibrin. J Biol Chem 1982; 257:2912-2919.
45. Hajjar KA, Hamel NM. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1989; 265:2908-2916.
46. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from culture human endothelial cells. J Clin Invest 1984; 74:1988-1995.
47. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells:modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109:97-104. Endothelial cells in culture are shown to produce greater amounts of t-PA and PAI-1 in response to thrombin and other stimuli.
48. Levin EG, Santell L. Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells. J Biol Chem 1988; 263:9360-9365.
49. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 1989; 243:1483-1485.
50. Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin-1. J Clin Invest 1986; 78:587-591.
51. Huang N, Lineberger B, Steiner M. Alpha-tocopherol, a potent modulator of endothelial cell function. Thromb Res 1988; 50:547-557.
52. Wiman B, Mellbring G, Ranby M, Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127:279-288.
53. Rijken DC, Juhan-Vague I, de Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101:274-284.
54. van Mourik JA, Lawrence DE, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259:14914-14921.
55. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77:165-169.
56. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1984; 75:818-824.
57. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68:1218-1223.
58. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
59. Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, et al. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993; 20:242-252.
60. Graf H. Endothelial control of cell migration and proliferation. Eur Heart J 1993; 14:183-186. This article describes the inhibitory effect of prostacyclin on proliferation of smooth muscle cells.
61. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky M. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981; 90:372-379.
62. Berk BD, Alexander RW. Vasoactive effects of growth factors [commentary]. Biochem Pharmacol 1989; 38:219-225.
63. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
64. Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R. The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1992; 1180:73-82.
65. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in hypercholesterolemic rabbits. J Clin Invest 1992; 90:1168-1172.
66. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89:2176-2182.
67. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14:753-759.
68. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791.
69. Sugiyama S, Kugiyama K, Ohgushi M, Fujumoto K, Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res 1994; 74:565-575.
70. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88:4651-4655.
71. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56-62.
72. Folland ED, Vogel RA, Hartigan P, Bates ER, Beauman GJ, Fortin T, et al. Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease. Circulation 1994; 89:2005-2014. The authors demonstrate that severity of stenosis is not correlated to severity of chronic ischemia.
73. Shimokawa H, Vanhoutte P. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 1989; 64:900-914.
74. Forstermann U, Mugge A, Alheid U, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988; 62:185-190.
75. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051. Authors of this study demonstrated that endothelial dysfunction is present in the coronary arteries of patients with coronary artery disease. Intracoronary infusion of acetylcholine induced paradoxical vasoconstriction in patients with moderate and severe coronary artery stenoses and vasodilatation in normal vessels.
76. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AD, et al. The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491-497. A clinical study in which coronary endothelial vasomotor dysfunction in patients with angiographically smooth coronary arteries was correlated to coronary risk factors such as serum cholesterol level, male sex, family medical history, age, and total number of risk factors.
77. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989; 79:287-291.
78. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993; 88:43-45.
79. Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 1993; 88:2923-2928.
80. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B, et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324:641-648.
81. Crossman DC, Larkin SW, Dashwood MR, Davies GJ, Yacoub M, Maseri A. Responses of atherosclerotic human coronary arteries in vivo to substance P. Circulation 1991; 84:2001-2010.
82. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989; 80:458-465.
83. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88:2510-2516.
84. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86:228-234. Forearm resistance vasodilator responses to methacholine and nitroprusside in 13 patients with hypercholesterolemia were blunted compared with those in 11 normal subjects. This shows that the effect of nitrovasodilators, including endothelium-derived relaxing factor, on the vascular smooth muscle of resistance vessels is less than normal in humans with hypercholesterolemia.
85. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
86. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88:2541-2547.
87. Vita JA, Keaney JF Jr. Ultrasound assessment of endothelial vasomotor function. In: Lanzer P, Lipton M (editors): Diagnostics of vascular diseases: principals and technology. Berlin: Springer; 1996. pp. 249-259. This chapter describes the noninvasive method used to measure flow-mediated vasodilatation of peripheral arteries.
88. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients < 40 years of age with coronary artery disease. Am J Cardiol 1996; 78:1210-1214. Ultrasound was used to demonstrate that flow-mediated vasodilatation in young patients with coronary artery disease was abnormal. Intra-arterial administration of L-NMMA was used to determine that the flow-mediated vasodilatation was mediated by EDRF.
89. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
90. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24:471-476.
91. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
92. Lieberman EH, Uehata A, Polak J, Ganz P, Selwyn AP, Creager MA, et al. Flow-mediated vasodilation is impaired in the brachial artery of patients with coronary disease or diabetes mellitus [abstract]. Clin Res 1993; 41:217A.
93. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein[a] level. J Clin Invest 1994; 93:50-55.
94. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
95. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986; 73:865-875.
96. Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge GH, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989; 83:1946-1952.
97. Vita JA, Treasure CB, Yeung AD, Vekshtein VI, Fantasia GM, Fish RD, et al. Patients with evidence of endothelial dysfunction as assessed by acetylcholine infusion demonstrate a marked increase in sensitivity to the constrictor effects of catecholamines. Circulation 1992; 85:1390-1397.
98. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:310-318.
99. van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson MH, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79:116-124.
100. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
101. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994; 90:5-11.
102. Okumura K, Yasue H, Matsuyama K, Ogawa H, Morikami Y, Obata K, et al. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992; 19:752-758.
103. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress and antioxidant protection in EDRF action. Prog Cardiovasc Dis 1995; 38:129-154. The authors review the role played by oxidative stress in the function of the vascular endothelium and examine the effects of treatment with antioxidants.
104. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67:1301-1308.
105. Creager MA, Gallagher SH, Girerd XJ, Coleman S, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90:1248-1253.
106. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-1550. Authors of this clinical study examined the effect of intracoronary infusion of L-arginine on coronary endothelial vasomotion in patients with hypercholesterolemia and in age-matched control subjects.
107. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB 1992; 6:3051-3064.
108. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frohlich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219:598-603.
109. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
110. Rosen GM, Greeman BA. Detection of superoxide generated by endothelial cells. Proc Natl Acad Sci USA 1984; 81:7269-7273.
111. Gryglewski RL, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320:454-456.
112. Mugge A, Elwell JH, Peterson TE, Harrison DG. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260:C219-C225.
113. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91:2546-2551.
114. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide production. J Clin Invest 1995; 95:2520-2529. In this experiment dietary treatment with probucol, a lipid-soluble antioxidant, was used to preserve action of EDRF in animals fed cholesterol.
115. Mugge A, Elwell JK, Peterson TE, Hofmayer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxation in cholesterol-fed rabbits. Circ Res 1991; 69:1293-1399.
116. Meredith IT, Anderson TJ, Young AC, Lieberman EH, Dyce MC, Gonenne A, et al. Superoxide dismutase restores endothelial vasodilator function in human coronary arteries in vivo [abstract]. Circulation 1993; 88:1467.
117. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1-7. In this placebo-controlled study flow-mediated vasodilatation of brachial artery was examined before and after oral administration of ascorbic acid.
118. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77:510-518.
119. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 1996; 93:8745-8749.
120. Pagano PJ, Ito Y, Tornheim K, Gallop P, Cohen RA. The superoxide generating system in rabbit aorta resembles NAD[P]H oxidase [abstract]. Circulation 1993; 88:1467.
121. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 1994; 14:1007-1013.
122. Weiss SJ, Young J, LoBuglio AF, Slivka A, Nimeh NF. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981; 68;714-722.
123. 2O2 and endothelium-dependent cerebral arteriolar dilation: implications for the identity of endothelium-derived relaxing factor generated by acetylcholine. Hypertension 1990; 16:162-169.
124. Marczin N, Ryan US, Catravas JD. Effects of oxidant stress on endothelium-derived relaxing factor-induced and nitrovasodilator-induced cGMP accumulation in vascular cells in culture. Circ Res 1992; 70:326-340.
125. Nagase S, Takemura K, Ueda A, Hirayama A, Aoyagi K, Kondoh M, et al. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine. Biochem Biophys Res Commun 1997; 233:150-153.
126. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem J 1992; 286:901-905.
127. Fantone JD, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 1982; 107:397-403.
128. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91:1044-1048.
129. Moreno JJ, Pryor WA. Inactivation of a-1-proteinase inhibitor by peroxynitrite. Chem Res Toxicol 1992; 5:425-431.
130. Stamler JS, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65:789-795.
131. Keaney FJ Jr, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993; 91:1582-1589.
132. Sies H. Hydroperoxides and thiol oxidants in the study of oxidative stress in intact cells and organs. In Sites H (editor): Oxidative stress: oxidants and antioxidants. London: Academic; 1985. pp. 73-91.
133. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76:333-337.
134. Negre-Salvayre A, Pieraggi MT, Mabile L, Salvayre R. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993; 99:207-217.
135. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10-18.
136. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344:160-162.
137. Inoue N, Hirata K, Yamada M, Hamamori Y, Matsuda Y, Akita H, et al. Lysophosphatidylcholine inhibits bradykinin-induced phosphoinositide hydrolysis and calcium transients in cultured bovine aortic endothelial cells. Circ Res 1992; 71:1410-1421.
138. Vidaver GA, Ting A, Lee JW. Evidence that lysolecithin is an important causal agent in atherosclerosis. J Theor Biol 1985; 115:27-41.
139. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JJ. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001.
140. Lopez JA, Armstrong ML, Piegors DJ, Heistad DD. Vascular responses to endothelin-1 in atherosclerotic primates. Arteriosclerosis 1990; 10:1113-1118.
141. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70:1191-1197.
142. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986; 232:87-90.
143. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85:929-932.
144. Elwood PD, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell WG. Ischemic heart disease and platelet aggregation: the Caerphilly Collaborative Heart Disease Study. Circulation 1991; 83:38-44.
145. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995; 74:626-630.
146. Weis JR, Pitas RE, Wilson BD, Rodgers GM. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB 1991; 5:2459-2469.
147. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13:1327-1333.
148. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel B, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71:912-918.
149. Théroux P, Latour JG, Léger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987; 75:156-162.
150. Andersen P, Arnesen J, Hjermann I. Hyperlipoproteinemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 1981; 209:199-202.
151. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen-activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168.
152. Hamsten A, Wiman BB, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
153. Hamsten A, deFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
154. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993; 73:335-343.
155. Vaughan DE, Shen C, Lazos S. Angiotensin II induces plasminogen activator inhibitor-1 [PAI-1] synthesis in vitro [abstract]. Circulation 1992; 86 (suppl 1):1557.
156. Ridker PM, Gavoury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87:1969-1973.
157. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
158. Alderman MH, Madhaven S, Ooi WL, Cohen H, Sealey JH, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
159. Aji W, Ravalli S, Szabolcs M, Jiang X, Sciacca RR, Michler RE, et al. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997; 95:430-437.
160. Suzuki M, Inauen W, Kvietys PR, Grisham MB, Moininger C, Schelling ME, et al. Superoxide mediates reperfusion-induced leukocyte-endothelial cell interactions. Am J Physiol 1989; 257:H1740-H1745.
161. Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68:499-508.
162. Kume N, Gimbrone MA. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994; 93:907-911.
163. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
164. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet 1994; 344:1383-1389.
165. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
166. Loscalzo J. Regression of coronary atherosclerosis. N Engl J Med 1990; 323:1337-1339.
167. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;
168. Leung WH, Lau CP, Waong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341:1496-1500.
169. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487. Authors of this placebo-controlled study investigated the effect of lipid-level-lowering therapy on endothelial function of coronary artery. Cholesterol-level lowering with lovastatin significantly improved endothelium-mediated responses in the coronary arteries of patients with atherosclerosis.
170. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493. Authors of this randomized trial showed that addition of antioxidant therapy (probucol) to lipid-level-lowering therapy resulted in greater improvement in coronary endothelial vasomotor function.
171. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
172. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary disease in men. N Engl J Med 1993; 328:1450-1456.
173. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786. A randomized, placebo-controlled trial of vitamin E (400-800 1U/day) treatment of patients known to have coronary artery disease. Authors of this study found a 77% reduction in incidence of nonfatal myocardial infarction and a 47% reduction in numbers of deaths and nonfatal infarctions.
174. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715-1720. In this primary prevention trial male smokers were randomly allocated vitamin E, β-carotene, both, or placebo, and evaluated for the development of lung cancer, other cancers, and overall mortality according to causes of death.
175. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci USA 1993; 90:11880-11884.
176. Keaney JF Jr, Guo Y, Cunningham D. Vascular incorporation of alpha- tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 1996; 98:386-394.
177. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97:22-28.
178. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96:1513-1519.
179. Briviba K, Sies H. Nonenzymatic antioxidant defense systems. In Frei B (editor): Natural antioxidants in human health and disease. San Diego: Academic Press; 1994. pp. 107-128.
180. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than pro-oxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 1993; 268:1304-1309.
181. Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit oxidative modification of low density lipoprotein. Atherosclerosis 1990; 82:185-191.
182. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 1994; 269:9397-9400.
183. Ghigo D, Alessio P, Foco A, Bussolino F, Costamagna C, Heller R, et al. Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells. Am J Physiol 1993; 265:C728-C732.
184. Komori Y, Hyun J, Chiang K, Fukuto JM. The role of thiols in the apparent activation of rat brain nitric oxide synthase (NOS). J Biochem 1995; 117:923-927.
185. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney JF. L-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary disease. J Clin Invest 1998; 101:1408-1414.
186. Creager MA, Roddy MA, Boles K, Stamler JS. N-acetylcysteine does not influence the activity of endothelium-derived relaxing factor in vivo. Hypertension 1997; 29:668-672.
187. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265:1861-1867.
188. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Post-menopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325:756-762.
189. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, et al. Estrogen replacement and coronary artery disease. Effect on survival in post-menopausal women. Arch Intern Med 1990; 150:2557-2562.
190. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280:605-613.
191. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1109.
192. Keaney JF Jr, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, et al. 17β-Estradiol preserves endothelial vasodilator function and limits LDL oxidation in hypercholesterolemic swine. Circulation 1994; 89:2251-2259.
193. Gerhard MD, Tawakol A, Halley EA. Long-term estradiol therapy with or without progesterone improves endothelium dependent vasodilatation in post-menopausal women [abstract]. Circulation 1996; 94 (suppl 1):1279.
194. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in post-menopausal women. Circulation 1994; 89:52-60.
195. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Pnysiol 1992; 263:H271-H275.
196. Paffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung D, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328:538-545.
197. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of exercise and incidence of myocardial infarction in women [abstract]. Circulation 1993; 88:1220.
198. Blair SN, Kohn HW III, Barlow CE, Paffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995; 273:1093-1098.
199. Wang J, Wolin MS, Hintze TH. Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs. Circ Res 1993; 73:829-838.
200. Muller JM, Meyers PR, Laughlin H. Vasodilator responses of coronary resistance arteries of exercise-trained pigs. Circulation 1994; 89:2308-2314.
201. Clarkson P, Montgomery H, Donald A, Powe A, Bull T, Dollery C, et al. Exercise training enhances endothelial function in young men [abstract]. J Am Coll Cardiol 1996; 27 (suppl A):288A. A brachial artery ultrasound technique is used to measure endothelium-dependent flow in young healthy men as a function of physical training. Results of this study showed that training enhanced endothelial function in young men of average fitness, even in the presence of cardiac risk factors.
202. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide: complex physiology and complex molecular adaptations. Circulation 1994; 90:2285-2290.
203. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 94:258-265.
204. Paul M, Zintz M, Bocker W, Dyer M. Characterization and functional analysis of the rat endothelin-1 promoter. Hypertension 1995; 25:683-693.
205. Horning B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-1118
206. Rubanyi GM. Reversal of hypercholesterolemia-induced endothelial dysfunction by L-arginine. Circulation 1991; 83:1118-1120.
207. Clarkson P, Adams MR, Powe AJ. Oral L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1994; 67:1989-1994.
208. Tawakol A, Omland T, Gerhard M, Wu J, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-1121.
209. Stroes E, Kastelein J, Cosentino F, Erkelens W, Weber R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99:41-46.
210. 2) by vascular tissues. Prostaglandins 1989; 37:401-410.
211. Beetens JR, Coene MC, Beheyen A, Zonnekenyn L, Herman AG. Vitamin C increases the prostacyclin production and decreases the vascular lesions in experimental atherosclerosis in rabbits. Prostaglandins 1986; 32:334-352.
212. Freedman JE, Farhat JH, Lock JM, Loscalzo J, Keaney JF Jr. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996; 94:2434-2440.
213. Rauramaa R, Salonen JT, Seppanen K, Salonen R, Venalainen JM, Ihanainen M, et al. Inhibition of platelet aggregability by moderate-intensity physical exercise; a randomized clinical trial in overweight men. Circulation 1986; 74:939-944.
214. Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer AI, et al. Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. Am J Cardiol 1992; 70:1051-1055.
215. Wolf A, Zalpour C, Theilmeier G, Wang B, Ma A, Anderson B, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29:479-485.
216. Koh KK, Mincenoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683-690.
217. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, et al. Effects of physical conditioning on fibrinolytic variables in young and old healthy adults. Circulation 1991; 83:1692-1697. Strenuous exercise for 6 months improved fibrinolytic parameters in healthy old subjects.
218. Faruqi R, De La Motte C, Dicorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 1994; 94:592-600.
219. Boscoboinik D, Szewczyk A, Azzi A. Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch Biochem Biophys 1991; 286:264-269.
220. Weber C, Erl W, Weber K, Weber P. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996; 93:1488-1492.
221. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen C, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
222. Caulin-Glaser T, Watson CA, Pari R, Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98:36-42.
223. Hernández-Presa M, Bustos C, Ortego M, Tuǹon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-1541.